Through validating the experimental processes, the key validated targets (i.e., MMP2, MYC, CASP3 and REG1A) and key pathways (i.e., metabolism-associated pathways) were identified as mechanisms of the anti-HCC effects of CKI. Here, MYC is linked to hepatocellular carcinoma.